Efficacy and safety of statin and fibrate combination therapy in lipid management

Diabetes and Metabolic Syndrome: Clinical Research and Reviews

Volumn 6, Issue 3, 2012, Pages 173-174

  Kota, Sunil Kumar ^a   Meher, Lalit Kumar ^b   Rao, Epari Sanjeeva ^c   Jammula, Sruti ^d   Modi, Kirtikumar D ^a  

^a Medwin Hospital   (India)

^b MKCG MEDICAL COLLEGE   (India)

^c Department of Pathology   (India)

^d ROLAND INSTITUTE OF PHARMACEUTICAL SCIENCES   (India)

Author keywords

Fibrates; Hyperlipidemia; Statin

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN C3; ATORVASTATIN; C REACTIVE PROTEIN; EOTAXIN 2; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CHOLESTEROL BLOOD LEVEL; CYTOKINE RELEASE; DIABETIC PATIENT; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; HUMAN; HYPERLIPIDEMIA; METABOLIC SYNDROME X; MONOCYTE; PLEIOTROPY; PRIORITY JOURNAL; REVIEW;

EID: 84869493296     PISSN: 18714021     EISSN: 18780334     Source Type: Journal    
DOI: 10.1016/j.dsx.2012.09.009     Document Type: Note

References (7)

1. M. Farnier Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing Vascular Health and Risk Management 4 2008 991 1000
2. S.M. Mohiuddin, K.M. Thakker, C.M. Setze, and M.T. Kelly Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: a post hoc analysis Current Medical Research and Opinion 27 2011 1067 1078
3. American Diabetes Association Clinical practice recommendations 1999 Diabetes Care 22 Suppl. 1 1999 S56 S59
4. E. Moutzouri, A. Kei, M.S. Elisaf, and H.J. Milionis Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid Vascular Health and Risk Management 6 2010 525 539
5. P. Costet, M.M. Hoffmann, B. Cariou, B. Guyomarc'h Delasalle, T. Konrad, and K. Winkler Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients Atherosclerosis 212 2010 246 251
6. D.C. Chan, G.F. Watts, E.M. Ooi, J. Ji, A.G. Johnson, and P.H. Barrett Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome Arteriosclerosis, Thrombosis, and Vascular Biology 28 2008 1831 1837
7. R. Krysiak, A. Gdula-Dymek, R. Bachowski, and B. Okopien Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes Diabetes Care 33 2010 2266 2270